Omeros | OMER - Ebitda


Omeros reported $-47.96M in EBITDA for its fiscal quarter ending in September of 2023.





Ebitda Change Date
Adma Biologics USD 73.59M 14.85M Dec/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Cytokinetics USD -169.32M 19.48M Mar/2026
Gilead Sciences USD 3.02B 1.01B Dec/2025
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Immunic USD -22.78M 753K Jun/2024
Insmed USD -148.3M 165.88M Mar/2026
Knight Therapeutics CAD 24.45M 3.46M Dec/2025
MacroGenics USD 21.95M 55.39M Sep/2025
Omeros USD -47.96M 7.39M Sep/2023
Pacira USD 40.24M 1.53M Mar/2026
Pfizer USD 5.99B 5.23B Mar/2026
Sarepta Therapeutics USD -252.2M 84.16M Dec/2025
United Therapeutics USD 379.5M 83.4M Dec/2025
Vertex Pharmaceuticals USD 1.19B 195.3M Mar/2026
Xoma USD 2.52M 7.98M Jun/2024